Development of autoimmune process in the organism is mainly due to disturbances in cytokine production. Hyperproduction of cytokines can be induced by certain viruses, bacteria, genetic factors, and other triggers. Cytokines act in an interrelated immune cascade with interferon-gamma (IFN-gamma) playing a central role.
View Article and Find Full Text PDFJ Investig Dermatol Symp Proc
December 2005
Ernst Schering Res Found Workshop
February 2006
We pioneered anticytokine therapy (ACT) for autoimmune diseases (ADs). In 1974, we proposed that hyperproduced interferon (IFN) can bring AD and anti-IFN can be therapeutic. In 1989, we proposed removing tumor necrosis factor (TNF)-alpha together with certain types of IFN to treat various ADs.
View Article and Find Full Text PDFWe pioneered anticytokine therapy (ACT) in 1974 and 1989, proposing to remove interferon (IFN) and tumor necrosis factor (TNF)-alpha together with IFNs to treat various autoimmune diseases, including AIDS. This hypothesis was confirmed in different laboratories and opened a new line to produce and test different anticytokines. We have had good, sometimes striking results treating various Th1-mediated autoimmune diseases, including inflammatory skin diseases, using anti-IFN-gamma and sometimes anti-TNF-alpha.
View Article and Find Full Text PDFExpert Rev Clin Immunol
May 2005
Anticytokine therapy was proposed in 1974 in Nature, in which it was stated that hyperproduced interferon can cause autoimmune disease and anti-interferon can be therapeutic. In 1989, the use of antibodies to tumor necrosis factor-alpha in combination with antibodies to certain types of interferon was proposed to treat various autoimmune diseases, including AIDS. The first anticytokine therapy was conducted in 1975.
View Article and Find Full Text PDF